---
title: "Weekly Recap | Abbott Laboratories +5.31%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302168564.md"
description: "Abbott Laboratories (ABT) rose 5.31% this week to close at $104.89, outperforming the S&P 500, which fell 1.95%, by 7.26 percentage points. Trading opened Monday at $100.00, dipped to an intraday low of $99.78, then climbed steadily over the following sessions. Thursday saw volume pick up as the stock closed at $104.68, and Friday (Oct 16) added a further gain to end at $104.89. The week’s range was 6.1%."
datetime: "2026-10-17T06:29:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302168564.md)
  - [en](https://longbridge.com/en/news/302168564.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302168564.md)
generator: "portal-rs"
---

# Weekly Recap | Abbott Laboratories +5.31%, most brokers rate it buy

## The Week

Abbott Laboratories (ABT) rose 5.31% this week to close at $104.89, outperforming the S&P 500, which fell 1.95%, by 7.26 percentage points. Trading opened Monday at $100.00, dipped to an intraday low of $99.78, then climbed steadily over the following sessions. Thursday saw volume pick up as the stock closed at $104.68, and Friday (Oct 16) added a further gain to end at $104.89. The week’s range was 6.1%.

## Key Events

The week’s company news centred on the colorectal cancer screening product Cologuard. On Monday, Abbott released new real-world evidence linking Cologuard screening to a 54% lower colorectal cancer incidence and lower odds of death. On Tuesday, the company launched a campaign encouraging Americans aged 45 and over to get screened. At the sector level, Johnson & Johnson’s MedTech revenue miss weighed on medical device makers early in the week, but Abbott shares outperformed peers on Friday. Rothschild & Co upgraded Abbott to buy from neutral this week, and TD Cowen reiterated its buy rating with a $135 price target on Friday.

## Analyst Ratings

Of 29 institutions covering Abbott, 19 rate it buy, 5 rate it overweight, and 4 rate it hold; none rate it underweight or sell. The consensus rating is strong buy, with a consensus target of $120.715, implying about 15.1% upside from the latest price. Targets range from $103.00 to $135.00, a spread of roughly $32. Abbott ranks 7th out of 142 peers in its medical device industry.

## The Week Ahead

Abbott reports fiscal Q3 2026 earnings before market open on Wednesday, Oct 21. The market expects EPS of $0.9638 on revenue of about $13 billion. With Johnson & Johnson’s MedTech miss having already pressured the segment, this report will test Abbott’s resilience across diagnostics and medical devices. On the macro side, US housing starts and building permits land on Oct 20, with the NAHB housing market index due Oct 19.

## In Short

Abbott moved against a falling market this week, with a predominantly positive ratings backdrop and latest-day money flows showing large-lot net buying alongside small-lot net selling. The valuation sits at 33.82x P/E and 3.57x P/B, relatively high by historical standards. The key tension: whether earnings can back up the current valuation and ratings expectations. Next Wednesday’s quarterly report is the main validation point.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

- [BUZZ-Street View: Abbott's nutrition spinoff to boost growth](https://longbridge.com/en/news/302696169.md)
- [Abbott lowers 2026 sales growth forecast on medical device weakness](https://longbridge.com/en/news/302555683.md)
- [Flyte Aviation’s LockeT shows fewer complications than Abbott’s Perclose in clinical study](https://longbridge.com/en/news/302777577.md)
- [Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company | ABT Stock News](https://longbridge.com/en/news/302555732.md)
- [Abbott Reports New Real-World Evidence Linking Cologuard® Screening to Lower Colorectal Cancer Incidence and Odds of Death](https://longbridge.com/en/news/301587478.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**